Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer.

IF 6.2 Q1 IMMUNOLOGY
ImmunoTargets and Therapy Pub Date : 2018-01-23 eCollection Date: 2018-01-01 DOI:10.2147/ITT.S134834
Olivier Belzile, Xianming Huang, Jian Gong, Jay Carlson, Alan J Schroit, Rolf A Brekken, Bruce D Freimark
{"title":"Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer.","authors":"Olivier Belzile,&nbsp;Xianming Huang,&nbsp;Jian Gong,&nbsp;Jay Carlson,&nbsp;Alan J Schroit,&nbsp;Rolf A Brekken,&nbsp;Bruce D Freimark","doi":"10.2147/ITT.S134834","DOIUrl":null,"url":null,"abstract":"<p><p>Phosphatidylserine (PS) is a negatively charged phospholipid in all eukaryotic cells that is actively sequestered to the inner leaflet of the cell membrane. Exposure of PS on apoptotic cells is a normal physiological process that triggers their rapid removal by phagocytic engulfment under noninflammatory conditions via receptors primarily expressed on immune cells. PS is aberrantly exposed in the tumor microenvironment and contributes to the overall immunosuppressive signals that antagonize the development of local and systemic antitumor immune responses. PS-mediated immunosuppression in the tumor microenvironment is further exacerbated by chemotherapy and radiation treatments that result in increased levels of PS on dying cells and necrotic tissue. Antibodies targeting PS localize to tumors and block PS-mediated immunosuppression. Targeting exposed PS in the tumor microenvironment may be a novel approach to enhance immune responses to cancer.</p>","PeriodicalId":30986,"journal":{"name":"ImmunoTargets and Therapy","volume":"7 ","pages":"1-14"},"PeriodicalIF":6.2000,"publicationDate":"2018-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/ITT.S134834","citationCount":"31","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ImmunoTargets and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/ITT.S134834","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 31

Abstract

Phosphatidylserine (PS) is a negatively charged phospholipid in all eukaryotic cells that is actively sequestered to the inner leaflet of the cell membrane. Exposure of PS on apoptotic cells is a normal physiological process that triggers their rapid removal by phagocytic engulfment under noninflammatory conditions via receptors primarily expressed on immune cells. PS is aberrantly exposed in the tumor microenvironment and contributes to the overall immunosuppressive signals that antagonize the development of local and systemic antitumor immune responses. PS-mediated immunosuppression in the tumor microenvironment is further exacerbated by chemotherapy and radiation treatments that result in increased levels of PS on dying cells and necrotic tissue. Antibodies targeting PS localize to tumors and block PS-mediated immunosuppression. Targeting exposed PS in the tumor microenvironment may be a novel approach to enhance immune responses to cancer.

Abstract Image

Abstract Image

Abstract Image

磷脂酰丝氨酸抗体靶向在癌症检测和免疫治疗中的应用。
磷脂酰丝氨酸(PS)是一种带负电荷的磷脂,存在于所有真核细胞中,活跃地隔离在细胞膜的内小叶上。PS暴露在凋亡细胞上是一个正常的生理过程,在非炎症条件下,通过主要在免疫细胞上表达的受体,通过吞噬吞噬触发它们快速清除。PS在肿瘤微环境中异常暴露,并参与整体免疫抑制信号,对抗局部和全身抗肿瘤免疫反应的发展。肿瘤微环境中PS介导的免疫抑制在化疗和放射治疗中进一步加剧,导致濒死细胞和坏死组织中PS水平升高。针对PS的抗体定位于肿瘤并阻断PS介导的免疫抑制。在肿瘤微环境中靶向暴露的PS可能是一种增强肿瘤免疫应答的新途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
16.50
自引率
0.00%
发文量
7
审稿时长
16 weeks
期刊介绍: Immuno Targets and Therapy is an international, peer-reviewed open access journal focusing on the immunological basis of diseases, potential targets for immune based therapy and treatment protocols employed to improve patient management. Basic immunology and physiology of the immune system in health, and disease will be also covered.In addition, the journal will focus on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信